Literature DB >> 2108185

The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries.

G F Erickson1, D A Magoffin, J R Cragun, R J Chang.   

Abstract

The objective of this work was to examine the effects of insulin-like growth factors (IGFs) on estradiol (E2) production by granulosa cells obtained from ovaries of patients with polycystic ovary disease (PCO). Granulosa cells, isolated from ovaries of three PCO patients, were cultured in serum-free medium containing either androstenedione alone (10(-7) M) or androstenedione plus graded doses of FSH, IGF-I, IGF-II, and/or insulin. At the end of the culture period (2, 4, or 6 days) E2 levels in the medium were measured by RIA. The results from each patient were similar, and therefore, the data were pooled. In the 6-day time-course experiments, the control (untreated) cells produced relatively high levels of E2 at 2 days; however, none was detected thereafter. Treatment with FSH (30 ng/mL) stimulated E2 production 4-fold at 2 days, but the stimulatory effects of FSH were not sustained during culture. IGF-I at 30 ng/mL mimicked the effects of FSH. Concomitant treatment with FSH and IGF-I caused synergistic increases in E2 production (3-, 13-, and 33-fold at 2, 4, and 6 days, respectively). Dose-response studies revealed that FSH and IGF-I stimulated E2 production in a dose-dependent fashion (ED50 of FSH and IGF-I, were 1.1 +/- 0.3 and 7.6 +/- 7.2 ng/mL, respectively). In the presence of a maximally effective dose of FSH (30 ng/mL), the cells appeared to become more responsive to IGF-I (ED50 of IGF-I plus FSH, 1.09 +/- 0.29 ng/mL); however, this effect was not significant (P = 0.086). In the presence of a maximally effective dose of IGF-I (30 ng/mL), the stimulatory effect of FSH on E2 production was dramatically amplified, but the IGF-I did not significantly (P = 0.85) change the potency of FSH (ED50 of FSH plus IGF-I, 1.07 +/- 2.3 ng/mL). Treatment with IGF-II over the concentration range of 0.1-100 ng/mL had no effect on either control or FSH-stimulated E2 production. Treatment with insulin, either alone or together with FSH, increased the levels of E2, but the insulin effects were seen only at the highest doses tested (0.3-10 micrograms/mL). The results in these in vitro experiments with PCO granulosa cells indicate that 1) physiological concentrations of IGF-I are as effective as FSH in stimulating E2 production; 2) IGF-I and FSH act synergistically to control the level of E2 production; and 3) this synergy was not observed with insulin or IGF-II.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108185     DOI: 10.1210/jcem-70-4-894

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Growth factors in the ovary.

Authors:  G Giordano; A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

2.  Survival, growth, and maturation of secondary follicles from prepubertal, young, and older adult rhesus monkeys during encapsulated three-dimensional culture: effects of gonadotropins and insulin.

Authors:  Jing Xu; Marcelo P Bernuci; Maralee S Lawson; Richard R Yeoman; Thomas E Fisher; Mary B Zelinski; Richard L Stouffer
Journal:  Reproduction       Date:  2010-08-20       Impact factor: 3.906

3.  Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.

Authors:  Annie A Guedikian; Alexandria Y Lee; Tristan R Grogan; David H Abbott; Karla Largaespada; Gregorio D Chazenbalk; Daniel A Dumesic
Journal:  Fertil Steril       Date:  2018-02-07       Impact factor: 7.329

4.  Synergy of Paracrine Signaling During Early-Stage Mouse Ovarian Follicle Development In Vitro.

Authors:  Hong Zhou; Joseph T Decker; Melissa M Lemke; Claire E Tomaszweski; Lonnie D Shea; Kelly B Arnold; Ariella Shikanov
Journal:  Cell Mol Bioeng       Date:  2018-08-09       Impact factor: 2.321

5.  The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.

Authors:  Malinda S Lee; Andrea Lanes; Andrey V Dolinko; Alexandra Bailin; Elizabeth Ginsburg
Journal:  J Assist Reprod Genet       Date:  2020-07-04       Impact factor: 3.412

Review 6.  Disordered follicle development.

Authors:  R Jeffrey Chang; Heidi Cook-Andersen
Journal:  Mol Cell Endocrinol       Date:  2012-07-31       Impact factor: 4.102

7.  Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.

Authors:  A M Fulghesu; M Ciampelli; C Belosi; R Apa; M Guido; A Caruso; S Mancuso; A Lanzone
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

Review 8.  Primate follicular development and oocyte maturation in vitro.

Authors:  Jing Xu; Min Xu; Marcelo P Bernuci; Thomas E Fisher; Lonnie D Shea; Teresa K Woodruff; Mary B Zelinski; Richard L Stouffer
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

10.  Immunohistochemical detection and distribution of the 1,25-dihydroxyvitamin D3 receptor in rat reproductive tissues.

Authors:  J A Johnson; J P Grande; P C Roche; R Kumar
Journal:  Histochem Cell Biol       Date:  1996-01       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.